The estimated Net Worth of Milton Boniuk is at least 245 千$ dollars as of 11 November 2015. Milton Boniuk owns over 25,000 units of NanoViricides Inc stock worth over 244,500$ and over the last 10 years Milton sold NNVC stock worth over 0$.
Milton has made over 16 trades of the NanoViricides Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Milton bought 25,000 units of NNVC stock worth 30,000$ on 11 November 2015.
The largest trade Milton's ever made was buying 405,954 units of NanoViricides Inc stock on 6 March 2015 worth over 1,047,361$. On average, Milton trades about 60,169 units every 21 days since 2014. As of 11 November 2015 Milton still owns at least 150,000 units of NanoViricides Inc stock.
You can see the complete history of Milton Boniuk stock trades at the bottom of the page.
Milton's mailing address filed with the SEC is 1111 HERMANN DRIVE, UNIT 29E, , HOUSTON, TX, 77004.
Over the last 15 years, insiders at NanoViricides Inc have traded over 1,608,110$ worth of NanoViricides Inc stock and bought 1,581,444 units worth 2,879,162$ . The most active insiders traders include Milton Boniuk、Anil Diwan、Pharma, Inc. Theracour. On average, NanoViricides Inc executives and independent directors trade stock every 77 days with the average trade being worth of 126,113$. The most recent stock trade was executed by Milton Boniuk on 11 November 2015, trading 25,000 units of NNVC stock currently worth 30,000$.
nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir
NanoViricides Inc executives and other stock owners filed with the SEC include: